252 related articles for article (PubMed ID: 36765282)
21. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
22. [The Expression of RTN1 in Lung Adenocarcinoma and
Its Effect on Immune Microenvironment].
Zhu S; Zu L; Xu S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
[TBL] [Abstract][Full Text] [Related]
23. Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity.
Li L; Huang Z; Du K; Liu X; Li C; Wang D; Zhang Y; Wang C; Li J
Front Pharmacol; 2022; 13():900699. PubMed ID: 35668930
[No Abstract] [Full Text] [Related]
24. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
25. CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer.
Yang K; Ma Y; Chen W; Liu L; Yang Z; He C; Zheng N; Liu X; Cheng X; Song J; Chen Y; Qiao H; Zhang R
Sci Rep; 2024 Apr; 14(1):8575. PubMed ID: 38609450
[TBL] [Abstract][Full Text] [Related]
26. ERH Impacts Patient Prognosis and Tumor Immune Microenvironment: A Pan-Cancer Analysis.
Gong Q; Li Q; Shen X; Xu Z
Comb Chem High Throughput Screen; 2024 Apr; ():. PubMed ID: 38584561
[TBL] [Abstract][Full Text] [Related]
27. Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity.
Shi YX; Yan JH; Liu W; Deng J
BMC Cancer; 2023 May; 23(1):408. PubMed ID: 37149576
[TBL] [Abstract][Full Text] [Related]
28. Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.
Zhao H; Xie R; Zhang C; Lu G; Kong H
Front Genet; 2022; 13():989460. PubMed ID: 36159971
[No Abstract] [Full Text] [Related]
29. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
Song J; Yang R; Wei R; Du Y; He P; Liu X
Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
[TBL] [Abstract][Full Text] [Related]
30. A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
Chen R; Wu W; Chen SY; Liu ZZ; Wen ZP; Yu J; Zhang LB; Liu Z; Zhang J; Luo P; Zeng WJ; Cheng Q
Front Immunol; 2022; 13():831542. PubMed ID: 35979347
[TBL] [Abstract][Full Text] [Related]
31. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract][Full Text] [Related]
32. A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker.
Huang Y; Zhou X; Li X; Huang D; Fang Z; Ding R
Oncol Res; 2023; 31(2):193-205. PubMed ID: 37304239
[TBL] [Abstract][Full Text] [Related]
33. Pan-cancer analysis of trophinin-associated protein with potential implications in clinical significance, prognosis, and tumor microenvironment in human cancers.
Li Z; Pu Z; Yang Z; Zhu Y; Deng Y; Li N; Peng F
Front Oncol; 2022; 12():971618. PubMed ID: 36419876
[TBL] [Abstract][Full Text] [Related]
34. Analysis of IGFBP7 expression characteristics in pan-cancer and its clinical relevance to stomach adenocarcinoma.
Xu HW; Wang MQ; Zhu SL
Transl Cancer Res; 2023 Oct; 12(10):2596-2612. PubMed ID: 37969374
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive pan-cancer investigation: unraveling the oncogenic, prognostic, and immunological significance of Abelson interactor family member 3 gene in human malignancies.
Sun A; Cai F; Xiong Q; Xie T; Li X; Xie Y; Luo R; Hu W; Zhong F; Wang S
Front Mol Biosci; 2023; 10():1277830. PubMed ID: 37942289
[No Abstract] [Full Text] [Related]
36. An integrative prognostic and immune analysis of PTPRD in cancer.
Ou C; Peng Q; Zeng C
Math Biosci Eng; 2022 Mar; 19(6):5361-5379. PubMed ID: 35603359
[TBL] [Abstract][Full Text] [Related]
37. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
38. Comprehensive pan-cancer analysis identifies the RNA-binding protein LRPPRC as a novel prognostic and immune biomarker.
Wu Z; Liu X; Xie F; Ma C; Lam EW; Kang N; Jin D; Yan J; Jin B
Life Sci; 2024 Apr; 343():122527. PubMed ID: 38417544
[TBL] [Abstract][Full Text] [Related]
39. PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer.
Zhao R; Chen S; Cui W; Xie C; Zhang A; Yang L; Dong H
Front Immunol; 2023; 14():1232047. PubMed ID: 37936713
[TBL] [Abstract][Full Text] [Related]
40. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
Front Genet; 2022; 13():938510. PubMed ID: 36171879
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
